18% Of the Population in UK is over 65 Years of Age This Accounts for 45% of Drug Dispensing.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c25312) has announced the addition of ADME ADME Absorption, Distribution, Metabolism, and Excretion ADME Association of Destination Management Executives ADME Active Duty Medical Extension in Children and The Elderly: Clinical Challenges and Opportunities to their offering. The elderly represent an increasingly important pharmaceutical market, for demographic reasons. For example, in the UK 18% of the population is over 65 years of age, but account for 45% of drug dispensing dispensing provision of drugs or medicines as set out properly on a lawful prescription. A prescription can only be filled, the drugs supplied, by a registered pharmacist, veterinarian, dentist or member of the medical profession. . Older patients tend to suffer from diseases such as liver and kidney impairment Impairment 1. A reduction in a company's stated capital. 2. The total capital that is less than the par value of the company's capital stock. Notes: 1. This is usually reduced because of poorly estimated losses or gains. 2. that require concurrent medications that modify the ADME profile. Planning and executing pharmacokinetic studies in both the elderly and pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. population can be problematic. For example, studies that enroll children need to examine the drugs' effect on some specific parameters, such as skeletal skeletal /skel·e·tal/ (skel´e-t'l) pertaining to the skeleton. skeletal pertaining to the skeleton. See also skeletal muscle. growth and other developmental aspects including psychomotor psychomotor /psy·cho·mo·tor/ (si?ko-mo´ter) pertaining to motor effects of cerebral or psychic activity. psy·cho·mo·tor adj. 1. milestones. Understanding the cases of these age-related changes, being able to quantify the effect and predict the potential outcomes is rapidly become a core competency A core competency is something that a firm can do well and that meets the following three conditions specified by Hamel and Prahalad (1990):
At least 95% of new drugs and biopharmaceuticals show a poor PK profile and other properties that could undermine profitability. ADME is the key for ensuring efficacy and tolerability tol·er·a·ble adj. 1. Capable of being tolerated; endurable. 2. Fairly good; passable. See Synonyms at average. tol . However, many drugs still fail due to poor ADME. This report examines the latest research on the causes and consequences of ADME changes in the elderly and children. Commercial considerations such as market size, demographics The attributes of people in a particular geographic area. Used for marketing purposes, population, ethnic origins, religion, spoken language, income and age range are examples of demographic data. , and the impact of ADME on the cost of drug development are thoroughly discussed. In addition, age related changes in ADME and in silico ADME profiles are detailed. The Report features exclusive interviews with key opinion leaders in the ADME arena as well as relevant case studies. Questions Answered --What are sources of age related ADME changes in the elderly? --What are sources of age related ADME changes in children? --What are the commercial considerations of ADME in children and the elderly? --What are the pressing issues for future research in this area? --What is the impact of ADME evaluation on the cost of drug development? --How will the discipline of ADME develop over the next five to ten years? --How can the value of ADME modeling in drug discovery be optimized? --Who are the key players in this space? Companies Mentioned: - Accelrys, Inc. - BASi (Bioanalytical Systems, Inc.) - BioFocus - Covance Inc. - DDS Medicines Research Ltd. - DxS Ltd - GeneGo Inc. - Kendle - Lhasa Limited - Molecular Devices Corporation - Nimbus Biotechnologie GmbH - NoAb BioDiscoveries Inc - Oxford Genome Sciences (UK) Ltd - Pharmaceutical Profiles Group - Pharmagene Laboratories Limited - Simulations Plus, Inc. - Tripos, Inc. For more information visit http://www.researchandmarkets.com/reports/c25312 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion